{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:39:44Z","timestamp":1790739584466,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":727,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1093\/annonc\/mdx496","type":"journal-article","created":{"date-parts":[[2017,8,30]],"date-time":"2017-08-30T19:10:12Z","timestamp":1504120212000},"page":"2806-2812","source":"Crossref","is-referenced-by-count":77,"title":["A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin\u2019s lymphoma (NHL): CALGB 50803 (Alliance)"],"prefix":"10.1016","volume":"28","author":[{"given":"P.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-H.","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Pitcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.L.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.A.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.D.","family":"Hsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.D.","family":"Cheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx496_bb0010","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx496_bb0015","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance)","volume":"33","author":"Leonard","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx496_bb0020","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx496_bb0025","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/cncr.25055","article-title":"Durable responses with the metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma","volume":"116","author":"Ruan","year":"2010","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdx496_bb0030","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrc1971","article-title":"The multifaceted circulating endothelial cell in cancer: towards marker and target identification","volume":"6","author":"Bertolini","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdx496_bb0035","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1158\/1078-0432.CCR-13-1442","article-title":"A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer","volume":"19","author":"Zhu","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"10.1093\/annonc\/mdx496_bb0040","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgamma RIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx496_bb0045","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/10543406.2010.536873","article-title":"Phase II cancer clinical trials with heterogeneous patient populations","volume":"22","author":"Jung","year":"2012","journal-title":"J Biopharmaceut Stat"},{"key":"10.1093\/annonc\/mdx496_bb0050","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1093\/annonc\/mdx496_bb0055","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric etimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1093\/annonc\/mdx496_bb0060","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1200\/JCO.2016.70.8651","article-title":"Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials","volume":"35","author":"Shi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx496_bb0065","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx496_bb0070","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdx496_bb0075","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx496_bb0080","doi-asserted-by":"crossref","first-page":"djv216","DOI":"10.1093\/jnci\/djv216","article-title":"the imperative for a new approach to toxicity analysis in oncology clinical trials","volume":"107","author":"Thanarajasingam","year":"2015","journal-title":"JNCI"},{"key":"10.1093\/annonc\/mdx496_bb0085","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/annonc\/mdn666","article-title":"Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma","volume":"20","author":"Ruan","year":"2009","journal-title":"Ann Oncol."},{"key":"10.1093\/annonc\/mdx496_bb0090","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1182\/blood-2013-03-490763","article-title":"Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes","volume":"121","author":"Ruan","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx496_bb0095","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx496_bb0100","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3324\/haematol.2011.050419","article-title":"Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone","volume":"97","author":"Persky","year":"2012","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdx496_bb0105","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/1078-0432.CCR-15-1848","article-title":"Fc gamma receptor 3A and 2A polymorphisms do not predict response to rituximab in follicular lymphoma","volume":"22","author":"Kenkre","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419346150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419346150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/11\/2806\/24169014\/mdx496.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:07:18Z","timestamp":1624694838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419346150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0923753419346150"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx496","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}